Liability clause in free-speech cases?

Share this article:

Recent First Amendment-related court decisions have opened the door to increased state tort product liability lawsuits that previously foundered because of FDA's strict authority over industry activity, according to a Washington Legal Foundation working paper.

While the Caronia and Sorrell decisions recognized due process and First Amendment protections for drug and medical device marketers' information dissemination, they have also invited new theories and approaches to state tort liability challenges, declares author and Strasburger & Price partner Michael A. Walsh in the paper.

“The emerging tort claims may be poorly fashioned and are initially being dismissed, but plaintiffs' lawyers will adapt and continue to advance more sophisticated pleadings,” Walsh says. “It will be years before this area of the law is settled.”

Walsh notes that the issue that has not yet been decided is whether the courts will recognize “intent” as a determination that is solely within FDA's expertise to determine.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?